Recommended Articles
Fundraising

seragy Raises €12M to Advance Quantitative Biomarkers for Neurodegenerative Disease Drug Development

By Angeled · October 14, 2026 · Fundraising
seragy Raises €12M to Advance Quantitative Biomarkers for Neurodegenerative Disease Drug Development
seragy Raises €12M to Advance Quantitative Biomarkers for Neurodegenerative Disease Drug Development

Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) share a common biological thread: misfolded proteins that clump together inside the brain, slowly destroying neurons. These conditions, known collectively as proteopathies, are among the most punishing unsolved problems in medicine — and a major reason why so many neurodegenerative drug trials fail is that developers lack precise, quantitative biomarkers to tell them whether a therapy is actually working. On October 14, 2026, Hanover, Germany-based seragy holding GmbH announced it has secured €12 million in financing to advance its SeRAS platform, a biomarker technology designed to generate molecular fingerprints of pathological protein aggregation from patient samples.

The Round

The €12 million financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG) — Lower Saxony's regional investment company for small and medium enterprises — and the State of Lower Saxony itself. The funds will accelerate development of the company's SeRAS® platform (Seed Replication, Analysis and Subtyping) and expand seragy's laboratory and analytical capabilities.

The financing coincides with a rebrand: the company, founded in 2022 as Prosperodes GmbH, now operates as seragy holding GmbH. Through its wholly owned subsidiary seragy analytics GmbH, it develops quantitative translational biomarkers for proteopathies — diseases driven by protein aggregation. The company is led by Dr. Christiane Ritter and Dr. Thorsten Lührs, two scientists with nearly three decades of expertise in protein aggregation research, alongside Arne Ungruh, an experienced business and finance leader.

In a separate validation of the technology, seragy was selected as one of five recipients of funding from The Michael J. Fox Foundation for Parkinson's Research through its Seed Amplification Assay Innovation Program. That grant supports development and evaluation of a quantitative biomarker assay for Parkinson's disease.

The Science: Molecular Fingerprints of Protein Aggregation

To understand what seragy is building, it helps to understand the diagnostic gap in neurodegenerative drug development. Many current assays for detecting pathological protein aggregates — such as alpha-synuclein in Parkinson's or tau and amyloid in Alzheimer's — are seed amplification assays that return essentially binary answers: the misfolded protein is present or it is not. That is useful for diagnosis but limited for drug development, where sponsors need to quantify how much aggregation is occurring, whether it is changing over time, and whether different molecular subtypes of the same disease respond differently to a given therapy.

seragy's SeRAS platform is designed to move beyond binary detection. It aims to produce quantitative, mechanism-relevant biomarkers: molecular fingerprints that reveal not just the presence of aggregation but its molecular patterns, allowing researchers to distinguish clinically relevant disease subtypes and measure biological change with the precision required for translational drug development. For pharmaceutical and biotechnology partners, this translates into support for more targeted therapeutic strategies — from early discovery through clinical development — by translating aggregation biology into actionable biomarker insights.

The strategic positioning is notable: rather than developing drugs itself, seragy is building the measurement layer that drug developers depend on. Biomarker strategy companies can work across many programs and sponsors simultaneously, and their technologies become embedded in trial designs across the industry.

Competitive and Clinical Context

The biomarker space for neurodegenerative diseases is heating up for good reason. The 2023 approval and 2024-2025 commercial rollout of anti-amyloid therapies such as lecanemab and donanemab for early Alzheimer's created enormous demand for precise, scalable biomarkers — both for patient selection and for monitoring treatment effect. Fluid biomarkers for Alzheimer's, particularly blood-based phosphorylated tau assays, have advanced rapidly, and regulators have begun accepting biomarker evidence as support for accelerated approvals.

In Parkinson's disease, the field is further behind: there are no disease-modifying therapies approved, and seed amplification assays for alpha-synuclein only became widely available in recent years. A quantitative assay that can subtype Parkinson's pathology and track it over time would be directly relevant to the next wave of clinical trials, including those targeting alpha-synuclein — exactly the gap seragy's Michael J. Fox Foundation grant targets.

Competitors in the neurodegeneration biomarker space include companies like C2N Diagnostics, Quanterix, and Alamar Biosciences in Alzheimer's fluid biomarkers, plus emerging seed-amplification platforms. seragy's differentiation is the combination of quantification and subtyping — molecular fingerprints rather than yes/no readouts — focused on proteopathies as a disease class rather than a single indication.

What This Means for Founders and Investors

The seragy raise illustrates several durable trends. First, enabling-technology companies that de-risk other companies' clinical programs continue to attract institutional and public capital, even when their revenue models are service- and partnership-driven. Second, the €12 million package — mixing commercial banking capital, a regional investment vehicle, and state support — reflects how European regions are actively building biotech ecosystems with blended public-private financing. For founders, the lesson is that non-dilutive and regionally backed capital can meaningfully complement venture funding, especially for platform companies with clear partnership pathways.

For investors, the bet is on the measurement layer becoming a bottleneck asset. As neurodegenerative pipelines grow — and as regulatory frameworks increasingly demand biomarker evidence of disease modification — platforms that can quantify what drugs are actually doing to protein aggregation become strategically valuable to every sponsor in the space. The Michael J. Fox Foundation's endorsement provides a form of scientific validation that is often more meaningful to pharma partners than a venture round alone.

Angeled.com connects founders with investors.

Read Next